Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults

References

• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Monto AS, Ansaldi F, Aspinall R et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 27(37), 5043–5053 (2009).
   PubMed Web of Science ®Google Scholar
• Franceschi C, Bonafè M, Valensin S et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 908, 244–254 (2000).
   PubMed Web of Science ®Google Scholar
• Almanzar G, Schwaiger S, Jenewein B et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J. Virol. 79(6), 3675–3683 (2005).
   PubMed Web of Science ®Google Scholar
• Pawelec G, Akbar A, Caruso C, Effros R, Grubeck-Loebenstein B, Wikby A. Is immunosenescence infectious? Trends Immunol. 25(8), 406–410 (2004).
   PubMed Web of Science ®Google Scholar
• Ouyang Q, Wagner WM, Voehringer D et al. Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp. Gerontol. 38(8), 911–920 (2003).
   PubMed Web of Science ®Google Scholar
• Lefebvre JS, Maue AC, Eaton SM, Lanthier PA, Tighe M, Haynes L. The aged microenvironment contributes to the age-related functional defects of CD4 T cells in mice. Aging Cell 11(5), 732–740 (2012).
   PubMed Web of Science ®Google Scholar
• Agrawal A, Su H, Chen J, Osann K, Agrawal S, Gupta S. Increased IL-21 secretion by aged CD4+ T cells is associated with prolonged STAT-4 activation and CMV seropositivity. Aging 4(9), 648–659 (2012).
   PubMedGoogle Scholar
• Laurence A, O’Shea JJ. T(H)-17 differentiation: of mice and men. Nat. Immunol. 8(9), 903–905 (2007).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176(10), 6333–6339 (2006).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Gravenstein S, Upshaw CM, Hooton JW, Krause P, Drinka P. Immune response to influenza vaccination in institutionalized elderly: effect on different T-cell subsets. Vaccine 16(4), 403–409 (1998).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Upshaw CM, Hooton JW, Lechelt KE, Meneilly GS. Responses to influenza vaccination in different T-cell subsets: a comparison of healthy young and older adults. Vaccine 16(18), 1742–1747 (1998).
   PubMed Web of Science ®Google Scholar
• Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 17(1), 82–94 (1999).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Gravenstein S, Upshaw CM et al. Granzyme B: a marker of risk for influenza in institutionalized older adults. Vaccine 19(27), 3744–3751 (2001).
   PubMed Web of Science ®Google Scholar
• Gardner EM, Murasko DM. Age-related changes in Type 1 and Type 2 cytokine production in humans. Biogerontology 3(5), 271–290 (2002).
   PubMed Web of Science ®Google Scholar
• Stout-Delgado HW, Du W, Shirali AC, Booth CJ, Goldstein DR. Aging promotes neutrophil-induced mortality by augmenting IL-17 production during viral infection. Cell Host Microbe 6(5), 446–456 (2009).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Ewen C, Zhou X et al. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 27(18), 2418–2425 (2009).
   PubMed Web of Science ®Google Scholar
• Hackett CJ, Eisenlohr LC. Virus entry and antigen biosynthesis in the processing and presentation of class-II MHC-restricted T-cell determinants of influenza virus. Immunol. Res. 9(2), 103–114 (1990).
   PubMed Web of Science ®Google Scholar
• Ennis FA, Rook AH, Qi YH et al. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet 2(8252), 887–891 (1981).
   PubMed Web of Science ®Google Scholar
• Demotz S, Grey HM, Sette A. The minimal number of class II MHC-antigen complexes needed for T cell activation. Science 249(4972), 1028–1030 (1990).
   PubMed Web of Science ®Google Scholar
• Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 207, 166–183 (2005).
   PubMed Web of Science ®Google Scholar
• Hackett CJ, Yewdell JW, Bennink JR, Wysocka M. Class II MHC-restricted T cell determinants processed from either endosomes or the cytosol show similar requirements for host protein transport but different kinetics of presentation. J. Immunol. 146(9), 2944–2951 (1991).
   PubMed Web of Science ®Google Scholar
• Lamb CA, Yewdell JW, Bennink JR, Cresswell P. Invariant chain targets HLA class II molecules to acidic endosomes containing internalized influenza virus. Proc. Natl Acad. Sci. USA 88(14), 5998–6002 (1991).
   PubMed Web of Science ®Google Scholar
• Askonas BA, Mullbacher A, Ashman RB. Cytotoxic T-memory cells in virus infection and the specificity of helper T cells. Immunology 45(1), 79–84 (1982).
   PubMed Web of Science ®Google Scholar
• Hosaka Y, Sasao F, Yamanaka K, Bennink JR, Yewdell JW. Recognition of noninfectious influenza virus by class I-restricted murine cytotoxic T lymphocytes. J. Immunol. 140(2), 606–610 (1988).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309(1), 13–17 (1983).
   PubMed Web of Science ®Google Scholar
• Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377(6548), 446–448 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson BJ, Costelloe EO, Fitzpatrick DR et al. Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc. Natl Acad. Sci. USA 100(5), 2657–2662 (2003).
   PubMed Web of Science ®Google Scholar
• Lawrence CW, Ream RM, Braciale TJ. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J. Immunol. 174(9), 5332–5340 (2005).
   PubMed Web of Science ®Google Scholar
• Gijzen K, Liu WM, Visontai I et al. Standardization and validation of assays determining cellular immune responses against influenza. Vaccine 28(19), 3416–3422 (2010).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Pinkoski MJ, Upshaw CM, Bleackley RC. The cell-mediated cytotoxic response to influenza vaccination using an assay for granzyme B activity. J. Immunol. Methods 190(1), 11–20 (1996).
   PubMed Web of Science ®Google Scholar
• Ewen C, Kane KP, Shostak I et al. A novel cytotoxicity assay to evaluate antigen-specific CTL responses using a colorimetric substrate for Granzyme B. J. Immunol. Methods 276(1-2), 89–101 (2003).
   PubMed Web of Science ®Google Scholar
• Boon AC, Fringuelli E, Graus YM et al. Influenza A virus specific T cell immunity in humans during aging. Virology 299(1), 100–108 (2002).
   PubMed Web of Science ®Google Scholar
• Jameson J, Cruz J, Terajima M, Ennis FA. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J. Immunol. 162(12), 7578–7583 (1999).
   PubMed Web of Science ®Google Scholar
• Wang M, Lamberth K, Harndahl M et al. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25(15), 2823–2831 (2007).
   PubMed Web of Science ®Google Scholar
• Richards KA, Chaves FA, Alam S, Sant AJ. Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins. Vaccine 31(1), 219–225 (2012).
   PubMed Web of Science ®Google Scholar
• Atmar RL, Keitel WA. Adjuvants for pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 323–344 (2009).
   PubMedGoogle Scholar
• McElhaney JE, Beran J, Devaster JM et al.; for the Influence65 Study Group. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect. Dis. (2013).
   PubMed Web of Science ®Google Scholar
• Huijskens E, Rossen J, Mulder P et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Clin. Vaccine Immunol. 18(9), 1401–1405 (2011).
   PubMed Web of Science ®Google Scholar
• Khurana S, Chearwae W, Castellino F et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2(15), 15ra5 (2010).
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4(2), e4384 (2009).
   PubMed Web of Science ®Google Scholar
• Eichelberger M, Golding H, Hess M et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, MD, USA, December 10–11, 2007. Vaccine 26(34), 4299–4303 (2008).
   PubMed Web of Science ®Google Scholar
• Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877–3882 (2009).
   PubMed Web of Science ®Google Scholar
• Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106(19), 7962–7967 (2009).
   PubMed Web of Science ®Google Scholar
• Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. Curr. Top. Microbiol. Immunol. 333, 413–429 (2009).
   PubMedGoogle Scholar
• Grewe M. Chronological ageing and photoageing of dendritic cells. Clin. Exp. Dermatol. 26(7), 608–612 (2001).
   PubMed Web of Science ®Google Scholar
• Haynes L. The effect of aging on cognate function and development of immune memory. Curr. Opin. Immunol. 17(5), 476–479 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou X, McElhaney JE. Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine 29(11), 2169–2177 (2011).
   PubMed Web of Science ®Google Scholar
• Coler RN, Baldwin SL, Shaverdian N et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5(10), e13677 (2010).
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Tel J, Sliepen KH et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 59(10), 1573–1582 (2010).
   PubMed Web of Science ®Google Scholar
• Canaday DH, Amponsah NA, Jones L, Tisch DJ, Hornick TR, Ramachandra L. Influenza-induced production of interferon-alpha is defective in geriatric individuals. J. Clin. Immunol. 30(3), 373–383 (2010).
   PubMed Web of Science ®Google Scholar
• Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17(20–21), 2517–2527 (1999).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. 4(7), 1129–1138 (2004).
   PubMed Web of Science ®Google Scholar
• Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J. Immunol. 172(6), 3437–3446 (2004).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Hottes TS, McElhaney JE et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J. Infect. Dis. 203(2), 158–167 (2011).
   PubMed Web of Science ®Google Scholar
• Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 28(38), 6145–6151 (2010).
   PubMed Web of Science ®Google Scholar
• Coler RN, Bertholet S, Moutaftsi M et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6(1), e16333 (2011).
   PubMed Web of Science ®Google Scholar
• Mbawuike IN, Acuna C, Caballero D et al. Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Cell. Immunol. 173(1), 64–78 (1996).
   PubMed Web of Science ®Google Scholar
• Clegg CH, Roque R, Van Hoeven N et al. Adjuvant solution for pandemic influenza vaccine production. Proc. Natl Acad. Sci. USA 109(43), 17585–17590 (2012).
   PubMed Web of Science ®Google Scholar
• Bertholet S, Ireton GC, Ordway DJ et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med. 2(53), 53ra74 (2010).
   PubMed Web of Science ®Google Scholar
• Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J. Immunol. 188(5), 2189–2197 (2012).
   PubMed Web of Science ®Google Scholar
• Behzad H, Huckriede AL, Haynes L et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 205(3), 466–473 (2012).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med. 117(8), 625–633 (1992).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351(22), 2286–2294 (2004).
   PubMed Web of Science ®Google Scholar
• Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59(1), 1–15 (2004).
   PubMed Web of Science ®Google Scholar
• Gorse GJ, O’Connor TZ, Young SL et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 21(17–18), 2133–2144 (2003).
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650–658 (2008).
   PubMed Web of Science ®Google Scholar